Table 2 “Breast cancer patient” is evaluated by 2-sample test for equality of proportions, but ‘No Breast cancer and no Ovarian cancer’ is evaluated by Fisher 's exact test
From: The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study
short-Pre | Post | P | |||
|---|---|---|---|---|---|
N | RRSO | N | RRSO | ||
Breast cancer patient (no ovarian cancer) | |||||
Total | 383 | 42 (11.0%) | 623 | 142 (22.8%) | <0.01 |
BRCA1 (35≦) | 170 | 23 (13.5%) | 243 | 65 (26.8%) | <0.01 |
BRCA2 (40≦) | 213 | 19 (8.9%) | 380 | 77 (20.3%) | <0.01 |
No breast cancer and no ovarian cancer | |||||
Total | 63 | 9(14.29%) | 87 | 3 (3.45%) | 0.03 |
BRCA1 (35≦) | 38 | 8(21.1%) | 48 | 3 (6.25%) | 0.05 |
BRCA2 (40≦) | 25 | 1(4%) | 39 | 0 (0%) | 0.39 |
